Patient-Centric Mission.
Asset-Centric Approach.
We’re pursuing our Orexin Receptor 2 Agonist Program to bring potentially transformative treatment options to patients with sleep-wake disorders.
Patient-Centric Mission.
Asset-Centric Approach.
We’re pursuing SerpinPC as a potential novel subcutaneous treatment for hemophilia B patients with potential expansion into other bleeding disorders.
Patient-Centric Mission.
Asset-Centric Approach.
We’re pursuing our LockBody® Technology Platform with the aim to redefine immuno-oncology treatment for patients with cancer.
We are leaders, innovators, and scientists aiming to pursue medicines that are transformational for patients.
Latest News
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024